- Home
- SIGA vs EIC Comparison
SIGA vs EIC Comparison
Compare SIGA & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- EIC
- Stock Information
- Founded
- SIGA 1995
- EIC N/A
- Country
- SIGA United States
- EIC United States
- Employees
- SIGA N/A
- EIC N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- SIGA Health Care
- EIC Finance
- Exchange
- SIGA Nasdaq
- EIC Nasdaq
- Market Cap
- SIGA 422.9M
- EIC 335.9M
- IPO Year
- SIGA 1997
- EIC 2019
- Fundamental
- Price
- SIGA $6.03
- EIC $12.93
- Analyst Decision
- SIGA
- EIC Strong Buy
- Analyst Count
- SIGA 0
- EIC 1
- Target Price
- SIGA N/A
- EIC $17.50
- AVG Volume (30 Days)
- SIGA 458.7K
- EIC 442.3K
- Earning Date
- SIGA 07-31-2025
- EIC 05-28-2025
- Dividend Yield
- SIGA 9.95%
- EIC 16.94%
- EPS Growth
- SIGA N/A
- EIC N/A
- EPS
- SIGA 0.67
- EIC 0.55
- Revenue
- SIGA $120,330,310.00
- EIC $51,224,692.00
- Revenue This Year
- SIGA N/A
- EIC $39.61
- Revenue Next Year
- SIGA $95.31
- EIC $27.28
- P/E Ratio
- SIGA $8.99
- EIC $23.44
- Revenue Growth
- SIGA N/A
- EIC 68.61
- 52 Week Low
- SIGA $4.95
- EIC $12.63
- 52 Week High
- SIGA $12.83
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- SIGA 51.95
- EIC 34.82
- Support Level
- SIGA $5.86
- EIC $12.63
- Resistance Level
- SIGA $6.23
- EIC $14.80
- Average True Range (ATR)
- SIGA 0.23
- EIC 0.25
- MACD
- SIGA -0.00
- EIC -0.12
- Stochastic Oscillator
- SIGA 57.14
- EIC 13.59
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.